Trimethoprim-sulfamethoxazole desensitization in AIDS.
Trimethoprim-sulfamethoxazole (TMS) desensitization was carried out in three patients with AIDS and Pneumocystis carinii pneumonia (PCP) in whom treatment with TMS had to be discontinued after 8 to 12 days due to an allergic reaction. Although the pneumonia was under control we decided for a desensitization to TMS because of the frequent reinfection and the high mortality rate particularly if treatment is incomplete. On the first day the patients took 0.4 mg/2 mg trimethoprim/sulfamethoxazole orally. The dose was increased during 9 successive days to 80 mg/400 mg trimethoprim/sulfamethoxazole. From the 10th to the 16th day 160 mg/800 mg trimethoprim/sulfamethoxazole was given daily and subsequently twice daily which is the recommended dose for prophylaxis of PCP. The desensitization was successful in two patients and a PCP prophylaxis was possible.
Papakonstantinou
G
G
Medizinische Poliklinik Ludwig-Maximilians-Universität München.
Füessl
H
H
Hehlmann
R
R
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000517:prevention & control*; D006801:Humans; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000209:etiology; D013420:Sulfamethoxazole / Q000009:adverse effects* / Q000627:therapeutic use; D014295:Trimethoprim / Q000009:adverse effects* / Q000627:therapeutic use
D014295:Trimethoprim; D013420:Sulfamethoxazole